Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 2, 2010, Pages 208-214

  Jansook, Phatsawee ^a   Stefánsson, Einar ^a   Thorsteinsdóttir, Margrét ^a,b   Sigurdsson, Baldur B ^b   Kristjánsdóttir, Sigrún S ^a   Bas, Jon Fernández ^a   Sigurdsson, Hakon H ^a   Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b ArcticMass Inc   (Iceland)

Author keywords

Carbonic anhydrase inhibitor; Cyclodextrin; Dorzolamide; Eye drop; Ocular drug delivery

Indexed keywords

2 HYDROXYPROPYL GAMMA CYCLODEXTRIN; BRINZOLAMIDE; CARBOXYMETHYLCELLULOSE; CYCLODEXTRIN; DORZOLAMIDE; EYE DROPS; GAMMA CYCLODEXTRIN; HYDROXYPROPYLMETHYLCELLULOSE; LUTROL F 127; METHAZOLAMIDE; POLOXAMER; POVIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; DRUG DELIVERY SYSTEM; DRUG FORMULARY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; IN VIVO STUDY; MUCOADHESION; NONHUMAN; PH; PHYSICAL CHEMISTRY; POSTERIOR EYE CHAMBER; RABBIT; SUSPENSION;

ADMINISTRATION, TOPICAL; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EXCIPIENTS; GAMMA-CYCLODEXTRINS; HYDROGEN-ION CONCENTRATION; METHAZOLAMIDE; METHYLCELLULOSE; POLYMERS; RABBITS; SOLUBILITY; SULFONAMIDES; SUSPENSIONS; THIAZINES; THIOPHENES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 77957261734     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.07.005     Document Type: Article

References (30)

1. Kaur I.P., Smitha R., Aggarwal D., Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int. J. Pharm. 2002, 248:1-14.
2. Kaur I.P., Singh M., Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int. J. Pharm. 2000, 199:119-127.
3. Mincione F., Menabuoni L., Supuran C.T. Clinical applications of carbonic anhydrase inhibitors in ophthalmology. Carbonic Anhydrase: Its Inhibitors and Activators 2004, 243-254. CRC Press, Boca Raton, Florida. C.T. Supuran, A. Scozzafava, J. Conway (Eds.).
4. Fridriksdottir H., Loftsson T., Stefansson E. Formulation and testing of methazolamide cyclodextrin eye drop solutions. J. Control. Release 1997, 44:95-99.
5. Putnam M.L., Schoenwald R.D., Duffel M.W., Barfknecht C.F., Segarra T.M., Campbell D.A. Ocular disposition of aminozolamide in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1987, 28:1373-1382.
6. Tous S.S., Nasser K.A.E. Acetazolamide topical formulation and ocular effect. S.T.P. Pharm. Sci. 1992, 2:125-131.
7. Lotti V.J., Schmitt C.J., Gautheron P.D. Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. 1984, 222:11-15.
8. Hathout R.M., Mansour S., Mortada N.D., Guinedi A.S. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. AAPS Pharm. Sci. Technol. 2007, 8:E1-E12.
9. El-Gazayerly O.N., Hikal A.H. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int. J. Pharm. 1997, 158:121-127.
10. Aggarwal D., Garg A., Kaur I.P. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J. Pharm. Pharmacol. 2004, 56:1509-1517.
11. Loftsson T., Frioriksdottir H., Stefansson E., Thorisdottir S., Guomundsson O., Sigthorsson T. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J. Pharm. Pharmacol. 1994, 46:503-504.
12. Loftsson T., Frithriksdottir H., Thorisdottir S., Stefansson E., Sigurthardottir A.M., Guthmundsson O., Sigthorsson T. 2-hydroxypropyl-β-cyclodextrin in topical carbonic-anhydrase inhibitor formulations. Eur. J. Pharm. Sci. 1994, 1:175-180.
13. Kaur I.P., Kapil M., Smitha R., Aggarwal D. Development of topically effective formulations of acetazolamide using HP-β-CD-polymer co-complexes. Curr. Drug Deliv. 2004, 1:65-72.
14. Guomundsdottir E., Stefansson E., Bjarnadottir G., Sigurjonsdottir J.F., Guomundsdottir G., Masson M., Loftsson T. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2000, 41:3552-3554.
15. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
16. Dodziuk H. Molecules with Holes-Cyclodextrins. Cyclodextrins and Their Complexes 2006, 1-30. Wiley-VCH Verlag, Weinheim, Germany. H. Dodziuk (Ed.).
17. Loftsson T., Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv. Drug Deliv. Rev. 1999, 36:59-79.
18. Schmid G. Preparation and application of γ-cyclodextrin. New Trends in Cyclodextrins and Derivatives 1991, 37-49. Editions de Santé, Paris, France. D. Duchene (Ed.).
19. Loftsson T., Hreinsdottir D., Masson M. Evaluation of cyclodextrin solubilization of drugs. Int. J. Pharm. 2005, 302:18-28.
20. Bin Choy Y., Park J.H., Prausnitz M.R. Mucoadhesive microparticles engineered for ophthalmic drug delivery. J. Phys. Chem. Solids 2008, 69:1533-1536.
21. Council of Europe S. European Pharmacopoeia 2006, Strasbourg, France. sixth ed.
22. Sinko P.J. Martin's Physical Pharmacy and Pharmaceutical Sciences 2006, Lippincott Williams & Wilkins, Philadelphia, pp. 501-503. fifth ed.
23. Sweetana S., Akers M.J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50:330-342.
24. Jansook P., Kurkov S.V., Loftsson T. Cyclodextrins as solubilizers: formation of complex aggregates. J. Pharm. Sci. 2010, 99:719-729.
25. Sigurdsson H.H., Stefansson E., Gudmundsdottir E., Eysteinsson T., Thorsteinsdottir M., Loftsson T. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J. Control. Release 2005, 102:255-262.
26. Ciba-Geigy Wissenschaftliche Tabellen Geigy 1977, Ciba-Geigy, Basel, Switzerland. eighth ed.
27. Sugrue M.F. The pharmacology of antiglaucoma drugs. Pharm. Ther. 1989, 43:91-138.
28. Loftsson T., Sigurdsson H.H., Konradsdottir F., Gisladottir S., Jansook P., Stefansson E. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 2008, 63:171-179.
29. Hall R., Havner G., Baker J., et al. Brinzolamide. Analytical Profiles of Drug Substances and Excipients 1999, vol. 26:47-96. Academic Press, San Diego, California.
30. DeSantis L. Preclinical overview of brinzolamide. Surv. Ophthalmol. 2000, 44:S119-S129.